Waystar Considers Sale Amid Market Challenges, Sources Reveal

Waystar, a provider of healthcare software solutions, is reportedly exploring strategic options including a potential sale, according to sources familiar with the situation. The company, known for its technology that automates and manages administrative tasks for hospitals and doctors, has engaged investment bank Evercore to assist in assessing its options. The discussions are said to be in preliminary stages, and there is no certainty that a sale will proceed, as per two anonymous sources.

Headquartered in Lehi, Utah, and Louisville, Kentucky, Waystar went public in 2024. However, its market valuation has recently fallen to approximately $4.8 billion, following a 24% decline in share price this year amid a broader downturn in the software sector. This potential sale could test investor interest in software firms, as the sector grapples with concerns over technological disruptions and market volatility.

Market Valuation and Strategic Positioning

Waystar has sought to differentiate itself by emphasizing its role as a technology company rather than a service provider that relies heavily on human resources. This positioning aimed to attract higher valuations typical of tech firms. Initially, this strategy was well-received, with shares climbing from $20 at the time of its public offering to a peak of $45 in 2025. However, investor sentiment shifted amid worries that advancements in artificial intelligence could impact software companies' market dynamics, as noted by Morgan Stanley analysts in a July report.

Waystar's origins trace back to a 2017 merger between Zirmed and Navicure, two healthcare revenue management companies. Its major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. EQT, which holds a 13% stake, remains the largest shareholder. CPPIB has a 10% stake, while BlackRock Institutional Trust Company owns 8%, according to LSEG data.

Stakeholder Responses and Market Implications

The stakeholders have remained largely silent on the matter, with EQT and BlackRock declining to comment and CPPIB not immediately responding to requests for comments. The outcome of Waystar's exploration of a sale could provide insights into the current appetite for investment in healthcare software companies, especially given the recent market fluctuations.

Waystar's situation underscores the challenges faced by publicly traded software companies in maintaining investor confidence amid technological shifts and market pressures. The company's decision to potentially return to private ownership may reflect broader trends in the technology sector, where companies seek stability and strategic growth outside the public markets.